\-\ Texto\\:\\ \ \(0\)\
\-\ exams\\:\\ thyroid\\,\\ cardiovascular\\,\\ lungs\\,\\ and\\ abdominal\\ exams\\ were\\ normal\\.\ \(0\)\
\-\ labs\\:\\ \ \(3\)\
\-\ cbc\\ indicated\\ normocytic\\ anemia\\.\\ \ \(0\)\
\-\ chemistry\\ panel\\ indicated\\ the\\ following\\ abnormalities\\:\ \(0\)\
\-\ glucose\\	\\	serum\\	127\\ \\(h\\)\\ \\	\ \(0\)\
\-\ urea\\ nitrogen\\	serum\\	33\\ \\(h\\)\ \(0\)\
\-\ creatinine\\	serum\\	2\\.2\\ \\(h\\)\\ \ \(0\)\
\-\ pt\\,ptt\\,inr\\:\\ normal\\	\ \(0\)\
\-\ feces\\ occult\\ blood\\ \\â\\€\\“\\ negative\\ on\\ 3\\ samples\\	\ \(0\)\
\-\ helicobacter\\ pylori\\ antibody\\ \\-\\ negative\ \(0\)\
\-\ due\\ to\\ this\\ patient\\â\\€\\™s\\ stage\\ iv\\ metastatic\\ disease\\,\\ surgery\\ was\\ not\\ indicated\\.\\ he\\ was\\ subsequently\\ referred\\ to\\ radiation\\ oncology\\ for\\ palliative\\ treatment\\.\ \(0\)\
\-\ barium\\ esophagram\\ \\(not\\ pictured\\)\ \(0\)\
\-\ conclusion\\:\ \(0\)\
\-\ lower\\ esophageal\\ stricture\\.\\ \\ this\\ is\\ most\\ concerning\\ for\\ malignancy\\ vs\\.\\ possible\\ peptic\\ stricture\\.\\ \\ recommend\\ gi\\ consult\\ for\\ direct\\ visualization\\.\ \(0\)\
\-\ \\ \\ \\ \ \(4545\)\
\-\ ct\\ oncology\\:\\ \ \(0\)\
\-\ impression\\:\ \(2\)\
\-\ findings\\ concerning\\ for\\ distal\\ esophageal\\ carcinoma\\ with\\ regional\\ nodal\\ metastases\\ and\\ possible\\ lung\\ metastases\\.\\ \\ in\\ particular\\,\\ the\\ juxtapleural\\ speculated\\ opacity\\ in\\ the\\ left\\ lower\\ lobe\\ may\\ reflect\\ an\\ area\\ of\\ rounded\\ atelectasis\\,\\ pneumonia\\,\\ or\\ metastatic\\ focus\\.\\ \\ correlate\\ with\\ pending\\ pet\\ scan\\.\ \(0\)\
\-\ pet\\ ct\\:\ \(0\)\
\-\ impression\\:\ \(2\)\
\-\ 1\\.\\ \\ findings\\ consistent\\ with\\ metabolically\\ active\\ mass\\ in\\ the\\ distal\\ esophagus\\ with\\ a\\ maximum\\ suv\\ of\\ 13\\.\\ \\ \ \(0\)\
\-\ 2\\.\\ \\ the\\ left\\ lower\\ lung\\ nodule\\ is\\ metabolically\\ active\\ with\\ a\\ max\\ suv\\ of\\ 5\\.1\\ consistent\\ with\\ metastatic\\ disease\\.\ \(0\)\
\-\ 3\\.\\ \\ multiple\\ nodal\\ metastatic\\ disease\\ involving\\ subcarinal\\ lymph\\ node\\,\\ left\\ infrahilar\\ lymph\\ node\\ and\\ abdominal\\ lymph\\ nodes\\.\ \(0\)\
\-\ 4\\.\\ \\ increased\\ metabolic\\ activity\\ present\\ in\\ the\\ left\\ adrenal\\ with\\ a\\ max\\ suv\\ of\\ 4\\.6\\ consistent\\ with\\ metastatic\\ disease\\.\ \(0\)\
\-\ squamous\\ cell\\ esophageal\\ cancer\ \(0\)\
\-\ peptic\\ stricture\ \(7\)\
\-\ achalasia\ \(51\)\
\-\ esophageal\\ carcinoma\ \(1\)\
\-\ 61\\ y\\.o\\.\\ man\\ presented\\ with\\ dysphagia\\ x\\ 6\\ weeks\\ with\\ solid\\ foods\\.\\ \\ he\\ was\\ able\\ to\\ tolerate\\ some\\ liquid\\ foods\\.\\ \\ he\\ had\\ modified\\ his\\ diet\\ due\\ to\\ these\\ symptoms\\.\\ \\ he\\ had\\ no\\ other\\ symptoms\\.\\ \\ \ \(0\)\
\-\ pmhx\\:\\ coronary\\ artery\\ disease\\ requiring\\ cabg\\ \\â\\€\\“\\ 2\\ vessel\\,\\ htn\\,\\ dm\\ type\\ i\\,\\ hyperlipidemia\\,\\ chronic\\ esophageal\\ reflux\\.\\ no\\ history\\ of\\ smoking\\.\\ \\ \\+30\\ year\\ history\\ of\\ alcohol\\ use\\.\ \(0\)\
\-\ esophageal\\ cancer\\ is\\ a\\ gi\\ malignancy\\ with\\ a\\ predilection\\ for\\ males\\ in\\ the\\ 6th\\-7th\\ decades\\ of\\ life\\.\\ \\ worldwide\\,\\ squamous\\ cell\\ carcinoma\\ is\\ more\\ prevalent\\ than\\ adenocarcinoma\\.\\ \\ however\\,\\ in\\ the\\ u\\.s\\.\\,\\ the\\ increased\\ incidence\\ of\\ adenocarcinoma\\ in\\ white\\ males\\ has\\ made\\ it\\ the\\ most\\ common\\ esophageal\\ malignancy\\.\\ \\ squamous\\ cell\\ carcinoma\\ remains\\ the\\ most\\ common\\ type\\ in\\ african\\-american\\ males\\.\\ \\ \ \(0\)\
\-\ two\\ primary\\ risk\\ factors\\ for\\ squamous\\ cell\\ carcinoma\\ of\\ the\\ esophagus\\ have\\ been\\ identified\\ in\\ developed\\ countries\\:\\ alcohol\\ consumption\\ and\\ cigarette\\ smoking\\.\\ \\ presumably\\,\\ it\\ is\\ for\\ this\\ reason\\ that\\ the\\ most\\ common\\ location\\ for\\ squamous\\ lesions\\ are\\ in\\ the\\ proximal\\ and\\ mid\\-portions\\ of\\ the\\ esophagus\\.\\ \\ in\\ asian\\ countries\\,\\ n\\-nitroso\\ compounds\\ found\\ in\\ smoked\\ foods\\ have\\ also\\ been\\ implicated\\ in\\ squamous\\ cell\\ lesions\\.\ \(0\)\
\-\ patients\\ usually\\ have\\ no\\ symptoms\\ until\\ late\\ in\\ the\\ course\\ of\\ disease\\ due\\ to\\ the\\ compliance\\ of\\ the\\ esophagus\\.\\ \\ the\\ first\\ symptom\\ is\\ usually\\ dysphagia\\ or\\ odynophagia\\ to\\ solid\\ foods\\.\\ \\ this\\ means\\ the\\ disease\\ is\\ often\\ quite\\ advanced\\ at\\ diagnosis\\ and\\ therefore\\ carries\\ a\\ very\\ poor\\ prognosis\\.\\ \\ \\ \ \(0\)\
\-\ esophageal\\ cancer\\ is\\ usually\\ suspected\\ after\\ an\\ abnormal\\ barium\\ esophagram\\ conducted\\ for\\ dysphagia\\.\\ \\ the\\ addition\\ of\\ ct\\ allows\\ for\\ further\\ assessment\\ of\\ metastatic\\ disease\\ and\\ regional\\ invasion\\.\\ \\ endoscopic\\ ultrasound\\ \\(eus\\)\\ is\\ often\\ obtained\\ when\\ no\\ evidence\\ of\\ metastatic\\ disease\\ exists\\ to\\ increase\\ the\\ accuracy\\ of\\ locoregional\\ metastases\\ and\\ staging\\ prior\\ to\\ surgery\\.\\ \\ fdg\\-pet\\ or\\ fdg\\-pet\\ ct\\ may\\ also\\ be\\ used\\ when\\ questions\\ exist\\ regarding\\ distant\\ metastasis\\.\\ \\ \\ it\\ has\\ been\\ found\\ in\\ previous\\ studies\\ that\\ pet\\ is\\ more\\ accurate\\ in\\ detecting\\ stage\\ iv\\ disease\\ than\\ ct\\ alone\\ or\\ in\\ combination\\ with\\ eus\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ esophageal\\:\\ 0\\.262614311141792\ \(0\)\
\-\ squamous\\:\\ 0\\.20744765569354381\ \(0\)\
\-\ foods\\:\\ 0\\.19333924118705165\ \(0\)\
\-\ pet\\:\\ 0\\.17790856353085024\ \(0\)\
\-\ the\\:\\ 0\\.16865234172601687\ \(0\)\
\-\ in\\:\\ 0\\.16247650387118873\ \(0\)\
\-\ disease\\:\\ 0\\.16127000636170044\ \(0\)\
\-\ metastatic\\:\\ 0\\.14749693098992678\ \(0\)\
\-\ suv\\:\\ 0\\.13681194984678974\ \(0\)\
\-\ esophagus\\:\\ 0\\.12655621518465418\ \(0\)\
\-\ of\\:\\ 0\\.12029536878011328\ \(0\)\
\-\ males\\:\\ 0\\.11888386069801445\ \(0\)\
\-\ eus\\:\\ 0\\.11741956355063135\ \(0\)\
\-\ for\\:\\ 0\\.11644554071536298\ \(0\)\
\-\ carcinoma\\:\\ 0\\.11490304018135374\ \(0\)\
\-\ metabolically\\:\\ 0\\.11354445834760116\ \(0\)\
\-\ stricture\\:\\ 0\\.1116376128253412\ \(0\)\
\-\ countries\\:\\ 0\\.11053869323561191\ \(0\)\
\-\ cell\\:\\ 0\\.10988766236671987\ \(0\)\
\-\ max\\:\\ 0\\.10808280431860183\ \(0\)\
\-\ is\\:\\ 0\\.10521349368727125\ \(0\)\
\-\ dysphagia\\:\\ 0\\.1041015050927355\ \(0\)\
\-\ serum\\:\\ 0\\.10335308085104365\ \(0\)\
\-\ esophagram\\:\\ 0\\.09487093988354212\ \(0\)\
\-\ indicated\\:\\ 0\\.09479653330265689\ \(0\)\
\-\ metastases\\:\\ 0\\.09317925883890489\ \(0\)\
\-\ he\\:\\ 0\\.09100168501493401\ \(0\)\
\-\ peptic\\:\\ 0\\.09058133747674407\ \(0\)\
\-\ with\\:\\ 0\\.09027543392572093\ \(0\)\
\-\ lymph\\:\\ 0\\.08962536253089615\ \(0\)\
\-\ nodal\\:\\ 0\\.0888594096595636\ \(0\)\
\-\ malignancy\\:\\ 0\\.08628585443313605\ \(0\)\
\-\ regional\\:\\ 0\\.0855341806515126\ \(0\)\
\-\ oncology\\:\\ 0\\.08219580367146403\ \(0\)\
\-\ most\\:\\ 0\\.07997798751556878\ \(0\)\
\-\ exams\\:\\ 0\\.07799610212946678\ \(0\)\
\-\ to\\:\\ 0\\.07683772636352545\ \(0\)\
\-\ cancer\\:\\ 0\\.07676964129507932\ \(0\)\
\-\ impression\\:\\ 0\\.07479926861897791\ \(0\)\
\-\ concerning\\:\\ 0\\.07370649972266874\ \(0\)\
\-\ ct\\:\\ 0\\.07313268422058151\ \(0\)\
\-\ usually\\:\\ 0\\.07255886355783617\ \(0\)\
\-\ smoking\\:\\ 0\\.0711634254123401\ \(0\)\
\-\ alcohol\\:\\ 0\\.07101935883860123\ \(0\)\
\-\ barium\\:\\ 0\\.06842092789046522\ \(0\)\
\-\ been\\:\\ 0\\.06715032211145608\ \(0\)\
\-\ due\\:\\ 0\\.06625216783152103\ \(0\)\
\-\ node\\:\\ 0\\.06604404269694991\ \(0\)\
\-\ common\\:\\ 0\\.06536420144761075\ \(0\)\
\-\ gi\\:\\ 0\\.06454582268743503\ \(0\)\
\-\ and\\:\\ 0\\.06351080074597805\ \(0\)\
\-\ symptoms\\:\\ 0\\.06306237237777576\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.06280264307056574\ \(0\)\
\-\ consistent\\:\\ 0\\.06249525971319657\ \(0\)\
\-\ juxtapleural\\:\\ 0\\.06144060878981534\ \(0\)\
\-\ stage\\:\\ 0\\.06119016527366048\ \(0\)\
\-\ it\\:\\ 0\\.05899870082781298\ \(0\)\
\-\ solid\\:\\ 0\\.05890808646163988\ \(0\)\
\-\ lower\\:\\ 0\\.0588967059400362\ \(0\)\
\-\ infrahilar\\:\\ 0\\.058709781775315675\ \(0\)\
\-\ locoregional\\:\\ 0\\.058709781775315675\ \(0\)\
\-\ have\\:\\ 0\\.05757744088061876\ \(0\)\
\-\ active\\:\\ 0\\.057058479051138214\ \(0\)\
\-\ compounds\\:\\ 0\\.055269346617805956\ \(0\)\
\-\ iv\\:\\ 0\\.054902413875323096\ \(0\)\
\-\ nitrogen\\:\\ 0\\.054041402159300915\ \(0\)\
\-\ feces\\:\\ 0\\.054041402159300915\ \(0\)\
\-\ helicobacter\\:\\ 0\\.054041402159300915\ \(0\)\
\-\ or\\:\\ 0\\.05346137365692502\ \(0\)\
\-\ normocytic\\:\\ 0\\.05300318991277768\ \(0\)\
\-\ urea\\:\\ 0\\.05300318991277768\ \(0\)\
\-\ pictured\\:\\ 0\\.05300318991277768\ \(0\)\
\-\ speculated\\:\\ 0\\.05300318991277768\ \(0\)\
\-\ this\\:\\ 0\\.05280606793324557\ \(0\)\
\-\ left\\:\\ 0\\.05242246048130783\ \(0\)\
\-\ samples\\:\\ 0\\.05210384955778582\ \(0\)\
\-\ possible\\:\\ 0\\.05206224892642469\ \(0\)\
\-\ type\\:\\ 0\\.05154609013638989\ \(0\)\
\-\ worldwide\\:\\ 0\\.051310575144801245\ \(0\)\
\-\ chemistry\\:\\ 0\\.05060096700179119\ \(0\)\
\-\ consumption\\:\\ 0\\.05060096700179119\ \(0\)\
\-\ often\\:\\ 0\\.05013700555166881\ \(0\)\
\-\ no\\:\\ 0\\.0499739012508682\ \(0\)\
\-\ cigarette\\:\\ 0\\.0499590483543868\ \(0\)\
\-\ smoked\\:\\ 0\\.0499590483543868\ \(0\)\
\-\ implicated\\:\\ 0\\.0499590483543868\ \(0\)\
\-\ found\\:\\ 0\\.049717902084394035\ \(0\)\
\-\ 127\\:\\ 0\\.049373022543286155\ \(0\)\
\-\ prevalent\\:\\ 0\\.049373022543286155\ \(0\)\
\-\ compliance\\:\\ 0\\.049373022543286155\ \(0\)\
\-\ reflect\\:\\ 0\\.04883393105536882\ \(0\)\
\-\ subcarinal\\:\\ 0\\.04833481029676291\ \(0\)\
\-\ questions\\:\\ 0\\.04833481029676291\ \(0\)\
\-\ conclusion\\:\\ 0\\.047870139987291525\ \(0\)\
\-\ exists\\:\\ 0\\.047870139987291525\ \(0\)\
\-\ negative\\:\\ 0\\.047570084864250545\ \(0\)\
\-\ pylori\\:\\ 0\\.04743546994177106\ \(0\)\
\-\ carries\\:\\ 0\\.04743546994177106\ \(0\)\
\-\ odynophagia\\:\\ 0\\.047027160196519244\ \(0\)\
\-\ lung\\:\\ 0\\.04674164431441692\ \(0\)\
\-\ when\\:\\ 0\\.04641479752080558\ \(0\)\
\-\ liquid\\:\\ 0\\.046278050191761795\ \(0\)\
\-\ tolerate\\:\\ 0\\.04593258738577643\ \(0\)\
\-\ exist\\:\\ 0\\.04560398328226325\ \(0\)\
\-\ cabg\\:\\ 0\\.044991283978393685\ \(0\)\
\-\ accuracy\\:\\ 0\\.044991283978393685\ \(0\)\
\-\ recommend\\:\\ 0\\.044704642927271394\ \(0\)\
\-\ modified\\:\\ 0\\.044704642927271394\ \(0\)\
\-\ presumably\\:\\ 0\\.044704642927271394\ \(0\)\
\-\ distal\\:\\ 0\\.044644979252209616\ \(0\)\
\-\ predilection\\:\\ 0\\.0444297048297818\ \(0\)\
\-\ conducted\\:\\ 0\\.0444297048297818\ \(0\)\
\-\ detecting\\:\\ 0\\.0444297048297818\ \(0\)\
\-\ lesions\\:\\ 0\\.044129124606506684\ \(0\)\
\-\ ptt\\:\\ 0\\.04391136851428683\ \(0\)\
\-\ antibody\\:\\ 0\\.04391136851428683\ \(0\)\
\-\ asian\\:\\ 0\\.04391136851428683\ \(0\)\
\-\ accurate\\:\\ 0\\.04391136851428683\ \(0\)\
\-\ than\\:\\ 0\\.04355746472335747\ \(0\)\
\-\ decades\\:\\ 0\\.043430088953189436\ \(0\)\
\-\ achalasia\\:\\ 0\\.043201760371276765\ \(0\)\
\-\ dm\\:\\ 0\\.04298091933668448\ \(0\)\
\-\ means\\:\\ 0\\.04298091933668448\ \(0\)\
\-\ reason\\:\\ 0\\.0427670903257563\ \(0\)\
\-\ correlate\\:\\ 0\\.042358780580504476\ \(0\)\
\-\ more\\:\\ 0\\.04219246165200904\ \(0\)\
\-\ hyperlipidemia\\:\\ 0\\.04216354812475352\ \(0\)\
\-\ abdominal\\:\\ 0\\.04202492098164735\ \(0\)\
\-\ allows\\:\\ 0\\.04197381591277173\ \(0\)\
\-\ diet\\:\\ 0\\.04178928250314842\ \(0\)\
\-\ increased\\:\\ 0\\.04155051519136611\ \(0\)\
\-\ palliative\\:\\ 0\\.041434724424854394\ \(0\)\
\-\ surgery\\:\\ 0\\.041311536192674095\ \(0\)\
\-\ occult\\:\\ 0\\.04126420776976167\ \(0\)\
\-\ quite\\:\\ 0\\.04126420776976167\ \(0\)\
\-\ inr\\:\\ 0\\.04109790183573202\ \(0\)\
\-\ maximum\\:\\ 0\\.04077712463387949\ \(0\)\
\-\ pmhx\\:\\ 0\\.04062228912235727\ \(0\)\
\-\ consult\\:\\ 0\\.040470933356777095\ \(0\)\
\-\ panel\\:\\ 0\\.040322904362378925\ \(0\)\
\-\ regarding\\:\\ 0\\.040322904362378925\ \(0\)\
\-\ endoscopic\\:\\ 0\\.04017805903531538\ \(0\)\
\-\ distant\\:\\ 0\\.04017805903531538\ \(0\)\
\-\ was\\:\\ 0\\.040168378161356065\ \(0\)\
\-\ staging\\:\\ 0\\.03924298889827206\ \(0\)\
\-\ creatinine\\:\\ 0\\.03911940656636265\ \(0\)\
\-\ symptom\\:\\ 0\\.03911940656636265\ \(0\)\
\-\ 61\\:\\ 0\\.03899805106473339\ \(0\)\
\-\ coronary\\:\\ 0\\.03887884356124737\ \(0\)\
\-\ cardiovascular\\:\\ 0\\.038761709337174675\ \(0\)\
\-\ may\\:\\ 0\\.03866747057750736\ \(0\)\
\-\ requiring\\:\\ 0\\.03831253972066972\ \(0\)\
\-\ htn\\:\\ 0\\.03831253972066972\ \(0\)\
\-\ had\\:\\ 0\\.038283681190834584\ \(0\)\
\-\ findings\\:\\ 0\\.037922797905401054\ \(0\)\
\-\ alone\\:\\ 0\\.03779018128016955\ \(0\)\
\-\ assessment\\:\\ 0\\.037592077347879255\ \(0\)\
\-\ particular\\:\\ 0\\.03749516850873876\ \(0\)\
\-\ glucose\\:\\ 0\\.03712090288713366\ \(0\)\
\-\ visualization\\:\\ 0\\.036766344808839634\ \(0\)\
\-\ remains\\:\\ 0\\.03659582815374691\ \(0\)\
\-\ late\\:\\ 0\\.03626722405023373\ \(0\)\
\-\ also\\:\\ 0\\.0361425483448043\ \(0\)\
\-\ advanced\\:\\ 0\\.03610874501786473\ \(0\)\
\-\ combination\\:\\ 0\\.035654524746364165\ \(0\)\
\-\ adrenal\\:\\ 0\\.03558171270617005\ \(0\)\
\-\ anemia\\:\\ 0\\.035298089825889674\ \(0\)\
\-\ has\\:\\ 0\\.03509751030754857\ \(0\)\
\-\ rounded\\:\\ 0\\.03495957394999005\ \(0\)\
\-\ metabolic\\:\\ 0\\.03482879220732454\ \(0\)\
\-\ invasion\\:\\ 0\\.03426980396011834\ \(0\)\
\-\ atelectasis\\:\\ 0\\.03421046394523261\ \(0\)\
\-\ direct\\:\\ 0\\.03386500113924724\ \(0\)\
\-\ therefore\\:\\ 0\\.03386500113924724\ \(0\)\
\-\ 33\\:\\ 0\\.03380910830294349\ \(0\)\
\-\ prognosis\\:\\ 0\\.03380910830294349\ \(0\)\
\-\ able\\:\\ 0\\.033698695205217594\ \(0\)\
\-\ vessel\\:\\ 0\\.033698695205217594\ \(0\)\
\-\ opacity\\:\\ 0\\.03343033109372678\ \(0\)\
\-\ that\\:\\ 0\\.033344953705466265\ \(0\)\
\-\ reflux\\:\\ 0\\.03327429983464331\ \(0\)\
\-\ incidence\\:\\ 0\\.03307172672626267\ \(0\)\
\-\ subsequently\\:\\ 0\\.032778852404800954\ \(0\)\
\-\ nodes\\:\\ 0\\.03263705668074221\ \(0\)\
\-\ focus\\:\\ 0\\.03254415799243231\ \(0\)\
\-\ factors\\:\\ 0\\.03249818478921082\ \(0\)\
\-\ poor\\:\\ 0\\.03240716924032911\ \(0\)\
\-\ cbc\\:\\ 0\\.0320549295951461\ \(0\)\
\-\ until\\:\\ 0\\.031969674683078826\ \(0\)\
\-\ pending\\:\\ 0\\.03159884443421896\ \(0\)\
\-\ life\\:\\ 0\\.031519138792480327\ \(0\)\
\-\ suspected\\:\\ 0\\.03147963693073295\ \(0\)\
\-\ normal\\:\\ 0\\.031372574956852556\ \(0\)\
\-\ addition\\:\\ 0\\.031096860743318723\ \(0\)\
\-\ increase\\:\\ 0\\.03084129980328586\ \(0\)\
\-\ not\\:\\ 0\\.030333944930434602\ \(0\)\
\-\ pneumonia\\:\\ 0\\.030324290460137016\ \(0\)\
\-\ nodule\\:\\ 0\\.030324290460137016\ \(0\)\
\-\ thyroid\\:\\ 0\\.030192870717364834\ \(0\)\
\-\ made\\:\\ 0\\.02963129156875295\ \(0\)\
\-\ use\\:\\ 0\\.02939598211158035\ \(0\)\
\-\ an\\:\\ 0\\.029382719503685102\ \(0\)\
\-\ history\\:\\ 0\\.029356690324103422\ \(0\)\
\-\ vs\\:\\ 0\\.029309818273868846\ \(0\)\
\-\ previous\\:\\ 0\\.02903031558920283\ \(0\)\
\-\ 13\\:\\ 0\\.028975780488640194\ \(0\)\
\-\ used\\:\\ 0\\.028761951477712017\ \(0\)\
\-\ developed\\:\\ 0\\.028503872082694604\ \(0\)\
\-\ referred\\:\\ 0\\.028428338041040415\ \(0\)\
\-\ course\\:\\ 0\\.02837844856758044\ \(0\)\
\-\ lungs\\:\\ 0\\.028353641732460196\ \(0\)\
\-\ activity\\:\\ 0\\.028206689398302662\ \(0\)\
\-\ studies\\:\\ 0\\.02818250607565562\ \(0\)\
\-\ metastasis\\:\\ 0\\.02815840927670924\ \(0\)\
\-\ abnormalities\\:\\ 0\\.027829805173196057\ \(0\)\
\-\ pt\\:\\ 0\\.027648987652285507\ \(0\)\
\-\ very\\:\\ 0\\.027560367319475622\ \(0\)\
\-\ risk\\:\\ 0\\.027451206937661548\ \(0\)\
\-\ identified\\:\\ 0\\.027238054713964097\ \(0\)\
\-\ obtained\\:\\ 0\\.027175402651742873\ \(0\)\
\-\ involving\\:\\ 0\\.02691044980162863\ \(0\)\
\-\ location\\:\\ 0\\.026752435559855105\ \(0\)\
\-\ labs\\:\\ 0\\.026617150274312988\ \(0\)\
\-\ first\\:\\ 0\\.025926703020815484\ \(0\)\
\-\ radiation\\:\\ 0\\.02545973052430373\ \(0\)\
\-\ white\\:\\ 0\\.025347876620470937\ \(0\)\
\-\ further\\:\\ 0\\.025023046710455802\ \(0\)\
\-\ area\\:\\ 0\\.024888490774292244\ \(0\)\
\-\ some\\:\\ 0\\.024172964310935616\ \(0\)\
\-\ proximal\\:\\ 0\\.024002114904768442\ \(0\)\
\-\ artery\\:\\ 0\\.023860859909554347\ \(0\)\
\-\ ultrasound\\:\\ 0\\.0236976541128043\ \(0\)\
\-\ primary\\:\\ 0\\.023623641850185017\ \(0\)\
\-\ his\\:\\ 0\\.023300297448712683\ \(0\)\
\-\ abnormal\\:\\ 0\\.02308171991544266\ \(0\)\
\-\ following\\:\\ 0\\.02304784701191764\ \(0\)\
\-\ weeks\\:\\ 0\\.02302535935122309\ \(0\)\
\-\ two\\:\\ 0\\.022815390067370832\ \(0\)\
\-\ chronic\\:\\ 0\\.022804518316630804\ \(0\)\
\-\ scan\\:\\ 0\\.022793664086850404\ \(0\)\
\-\ however\\:\\ 0\\.022739653788416914\ \(0\)\
\-\ presented\\:\\ 0\\.022403880926248194\ \(0\)\
\-\ blood\\:\\ 0\\.022312384525753022\ \(0\)\
\-\ lobe\\:\\ 0\\.02220221771358915\ \(0\)\
\-\ evidence\\:\\ 0\\.02180677562823603\ \(0\)\
\-\ these\\:\\ 0\\.021695296424568626\ \(0\)\
\-\ patients\\:\\ 0\\.02161288148309475\ \(0\)\
\-\ prior\\:\\ 0\\.021495590339878027\ \(0\)\
\-\ man\\:\\ 0\\.02033958299379992\ \(0\)\
\-\ other\\:\\ 0\\.019951689225536577\ \(0\)\
\-\ diagnosis\\:\\ 0\\.01991622285542253\ \(0\)\
\-\ were\\:\\ 0\\.0198039694548992\ \(0\)\
\-\ present\\:\\ 0\\.019714121405582017\ \(0\)\
\-\ multiple\\:\\ 0\\.0187916497807288\ \(0\)\
\-\ after\\:\\ 0\\.018637766767603956\ \(0\)\
\-\ treatment\\:\\ 0\\.018301086898904573\ \(0\)\
\-\ be\\:\\ 0\\.015585119345746402\ \(0\)\
\-\ mass\\:\\ 0\\.014675095440337991\ \(0\)\
\-\ are\\:\\ 0\\.014578325842829547\ \(0\)\
\-\ at\\:\\ 0\\.014511405012839993\ \(0\)\
\-\ patient\\:\\ 0\\.012495825704686816\ \(0\)\
\-\ year\\:\\ 0\\.01184003025935115\ \(0\)\
\-\ on\\:\\ 0\\.01160324729918076\ \(0\)\
